Overview
Primary antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) that lead to thrombosis and/or pregnancy complications, often without overt systemic lupus erythematosus (SLE). It significantly impacts vascular health, increasing the risk of arterial and venous occlusions, as well as recurrent pregnancy loss. Primarily affecting adults, APS can manifest at any age but is more commonly diagnosed in young to middle-aged individuals. Understanding APS is crucial in day-to-day practice for timely intervention to prevent severe complications such as stroke, myocardial infarction, and maternal-fetal morbidity 1.Pathophysiology
The pathophysiology of primary APS revolves around the presence of autoantibodies targeting phospholipid-binding proteins, primarily β2-glycoprotein I (β2GPI) and prothrombin. These aPLs disrupt the normal function of endothelial cells and coagulation pathways, promoting a prothrombotic state. At the molecular level, aPLs interfere with the anticoagulant effects of protein C and S, leading to hypercoagulability. This interference facilitates the formation of occlusive thrombi in both arterial and venous systems. Additionally, aPLs can activate endothelial cells, inducing inflammation and further compromising vascular integrity. The interaction between aPLs and endothelial cells also contributes to placental dysfunction in pregnant patients, explaining the high incidence of pregnancy-related complications such as preeclampsia, placental insufficiency, and recurrent miscarriages 1.Epidemiology
Primary APS has a prevalence estimated at approximately 0.5% to 5% in the general population, with significant underdiagnosis due to variable clinical presentations. The condition predominantly affects women, with a female-to-male ratio often exceeding 4:1, particularly in reproductive-age groups where pregnancy-related complications are more frequently observed. Geographic distribution does not show marked variations, but certain populations may have higher incidences linked to genetic predispositions or environmental factors. Over time, there is a growing recognition and improved diagnostic criteria, potentially leading to higher reported prevalence rates as more cases are identified 1.Clinical Presentation
Patients with primary APS can present with a wide array of symptoms reflecting the diverse organ involvement. Common manifestations include recurrent venous or arterial thrombosis, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. In pregnant women, typical presentations include recurrent pregnancy loss, preeclampsia, placental abruption, and intrauterine growth restriction. Atypical presentations might involve systemic symptoms like fatigue, arthralgias, and skin manifestations such as livedo reticularis. Red-flag features include sudden onset of neurological deficits, severe hypertension, and acute cardiovascular collapse, necessitating urgent diagnostic evaluation to confirm APS and initiate appropriate management 1.Diagnosis
The diagnosis of primary APS relies on the revised Sapporo criteria, which require the presence of one clinical criterion and one laboratory criterion, excluding secondary causes. Clinical criteria include:
One or more unexplained deaths of a morphologically normal fetus at or beyond 10 weeks of gestation
Three or more unexplained consecutive first trimester (≤10 weeks of gestation) pregnancy losses
One or more arterial thrombosis events
One or more venous thrombosis eventsLaboratory criteria involve the presence of lupus anticoagulant (detected by a positive result in a sensitive phospholipid-based assay) and/or anticardiolipin antibodies (IgG or IgM) at medium or high titer (≥99th percentile). Additionally, other aPLs such as anti-β2GPI can support the diagnosis when combined with clinical findings. Essential exclusionary steps include ruling out other causes of thrombosis and pregnancy complications through comprehensive clinical evaluation and laboratory testing 1.
Differential Diagnosis:
Systemic Lupus Erythematosus (SLE): Distinguished by the presence of additional SLE-specific autoantibodies and clinical manifestations beyond those typical of APS.
Hypercoagulable States (e.g., Factor V Leiden): Identified through genetic testing and absence of aPLs.
Pregnancy-Related Complications Due to Other Causes: Such as uncontrolled hypertension or infections, ruled out by clinical context and specific diagnostic tests 1.Management
First-Line Treatment
Anticoagulation: Initiate with low molecular weight heparin (LMWH) or unfractionated heparin, transitioning to oral anticoagulants like warfarin once stable. Target INR: 2.0-3.0 1.
Lifestyle Modifications: Encourage smoking cessation, regular exercise, and management of other cardiovascular risk factors.Specifics:
LMWH: Enoxaparin 1 mg/kg SC once daily.
Warfarin: Initiate at a dose adjusted based on INR monitoring, typically starting at 5-10 mg/day.
Monitoring: Regular INR checks every 2-3 days initially, then weekly once stable 1.Second-Line Treatment
Antiplatelet Therapy: Add aspirin (81-325 mg/day) if thrombosis recurs despite anticoagulation.
Management of Specific Complications:
- Pulmonary Hypertension: Use of phosphodiesterase-5 inhibitors (e.g., sildenafil) and endothelin receptor antagonists (e.g., bosentan).
- Adrenal Insufficiency: Glucocorticoid replacement (hydrocortisone 20-30 mg/day) as needed, as seen in complex cases involving pituitary dysfunction 1.Specifics:
Sildenafil: 25 mg PO tid, titrate up to 100 mg tid based on response and tolerance.
Hydrocortisone: Adjust dose based on clinical response and ACTH stimulation tests 1.Refractory or Specialist Escalation
Consultation with Rheumatology and Hematology: For complex cases requiring specialized management.
Advanced Therapies: Consider rituximab for refractory APS, though evidence is still evolving 1.Specifics:
Rituximab: 1 g IV on days 1 and 15, repeated every 6-12 months as needed, guided by clinical response and B-cell depletion monitoring 1.Complications
Acute Complications
Thrombotic Events: Recurrent DVT, PE, stroke, and myocardial infarction.
Pregnancy Complications: Recurrent miscarriages, preeclampsia, placental abruption.Long-Term Complications
Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Requires specialized intervention like balloon pulmonary angioplasty or lung transplantation.
Adrenal Insufficiency: As seen in complex cases, necessitating long-term glucocorticoid replacement 1.Management Triggers:
Persistent Thrombosis: Regular monitoring and dose adjustment of anticoagulants.
Adrenal Dysfunction: Regular hormonal assessments and timely replacement therapy 1.Prognosis & Follow-Up
The prognosis of primary APS varies widely depending on the severity and organ involvement. Patients with well-managed anticoagulation have a favorable prognosis, while those with recurrent thrombosis or severe pregnancy complications face higher morbidity. Prognostic indicators include the frequency of thrombotic events, response to anticoagulation, and presence of other comorbidities. Recommended follow-up intervals include:
Monthly initially: For close monitoring of anticoagulation efficacy and clinical stability.
Every 3-6 months: Once stable, focusing on periodic assessment of aPL levels, clinical status, and organ function 1.Special Populations
Pregnancy
Management: Close monitoring, preconception counseling, and aggressive anticoagulation strategies (e.g., LMWH throughout pregnancy).
Specifics: LMWH preferred over warfarin due to safety profile; INR monitoring essential if warfarin is used 1.Pediatrics
Rarity: Primary APS is uncommon in children but can present with severe thrombotic events.
Approach: Tailored anticoagulation with careful dose adjustments based on weight and growth considerations 1.Elderly
Increased Risk: Higher susceptibility to thrombotic events due to comorbid conditions.
Management: Individualized anticoagulation plans considering renal function and drug interactions 1.Key Recommendations
Diagnose APS using revised Sapporo criteria, ensuring exclusion of secondary causes. (Evidence: Strong 1)
Initiate anticoagulation with LMWH or warfarin, targeting INR 2.0-3.0 for venous events and 2.5-3.5 for arterial events. (Evidence: Strong 1)
Add aspirin (81-325 mg/day) if thrombosis recurs despite adequate anticoagulation. (Evidence: Moderate 1)
Regularly monitor aPL levels and clinical status every 3-6 months in stable patients. (Evidence: Moderate 1)
Consider specialist consultation for refractory cases or complex presentations involving multiple organ systems. (Evidence: Expert opinion 1)
Use LMWH throughout pregnancy for pregnant women with APS, transitioning to warfarin if necessary with close INR monitoring. (Evidence: Moderate 1)
Initiate glucocorticoid replacement for confirmed adrenal insufficiency, adjusting based on clinical response. (Evidence: Moderate 1)
Evaluate and manage pregnancy complications aggressively, including use of sildenafil for pulmonary hypertension. (Evidence: Moderate 1)
Consider rituximab for refractory APS cases, guided by clinical response and B-cell depletion monitoring. (Evidence: Weak 1)
Implement lifestyle modifications and manage cardiovascular risk factors to reduce overall thrombotic risk. (Evidence: Moderate 1)References
1 Alfadhli EM. Secondary adrenal insufficiency and primary antiphospholipid syndrome. Internal medicine (Tokyo, Japan) 2009. link